Immunotherapy in head and neck cancer: aiming at EXTREME precision
Abstract Background Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic treatment often forms an integral part of their management. Immunotherapy is based on functional restoration of t...
Main Authors: | Petr Szturz, Jan B. Vermorken |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-06-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12916-017-0879-4 |
Similar Items
-
Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice
by: Petr Szturz, et al.
Published: (2019-06-01) -
Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
by: Petr Szturz, et al.
Published: (2016-08-01) -
Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
by: Ronan W. Hsieh, et al.
Published: (2021-09-01) -
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
by: Sandra Ortiz-Cuaran, et al.
Published: (2021-02-01) -
Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study
by: Hui-Ching Wang, et al.
Published: (2020-09-01)